Findings seen for COVID-19 infection, hospitalization, and mortality
Patients with schizophrenia, mood disorders, anxiety disorders have increased odds of COVID-19 mortality
Relative risks for mortality significantly reduced for any SSRI, fluoxetine, and fluoxetine or fluvoxamine
2015 to 2019 saw increase in all-cause mortality rates, mortality for drug/alcohol poisoning
Two-year trajectory of depression symptoms significantly linked to cancer survival; association for anxiety not significant
COVID-19 standardized mortality rates were elevated across nine psychiatric conditions including learning disabilities, eating disorders
Risk for loss was 1.1 to 4.5 times higher among children of racial/ethnic minorities compared with non-Hispanic Whites
Fatal opioid overdoses four times more likely in the two days after hospital discharge
People with multiple sclerosis, with or without depression, have increased risks for incident vascular disease, all-cause mortality
Benzodiazepine deaths increased from April-June 2019 to April-June 2020, with larger increase for illicit benzodiazepine deaths